GSA Capital Partners’s Avidity Biosciences RNAM Stock Holding History

GSA Capital Partners’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,284	Closed	-$598K	–	2097
2025 Q4	$598K	Buy	+8,284	New	+$535K	0.05%	692
2025 Q1	–	Sell	-7,320	Closed	-$213K	–	2012
2024 Q4	$213K	Buy	+7,320	New	+$306K	0.02%	1383
2024 Q1	–	Sell	-144,202	Closed	-$1.3M	–	1914
2023 Q4	$1.3M	Sell	144,202 -195,477	-58%	-$1.31M	0.11%	272
2023 Q3	$2.17M	Buy	339,679 +282,270	+492%	+$2.43M	0.19%	91
2023 Q2	$637K	Buy	57,409 +26,747	+87%	+$335K	0.06%	584
2023 Q1	$471K	Sell	30,662 -20,977	-41%	-$462K	0.05%	752
2022 Q4	$1.15M	Buy	+51,639	New	+$770K	0.14%	153

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

GSA Capital Partners's RNAM Position: Q1 2026 in Review

GSA Capital Partners sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 8,284 shares — an estimated $598K sold.

GSA Capital Partners first reported a position in RNAM in Q4 2022 and held it in 7 quarters. The position peaked at $2.17M in Q3 2023. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

GSA Capital Partners reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 8,284 Avidity Biosciences shares in Q1 2026, an estimated $598K.
GSA Capital Partners first reported a position in Avidity Biosciences in Q4 2022 and held it in 7 quarters.
GSA Capital Partners's Avidity Biosciences position peaked at $2.17M in Q3 2023.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.